Armistice Capital LLC recently announced the acquisition of new stake in Predictive Oncology Inc. (NASDAQ:POAI). The institutional investor has increased its shareholding in the Healthcare company by 86.39% to 0.48 million shares with purchase of 0.22 million shares. This fresh investment now brings its stake to 3.34% valued currently at $0.79 million. In addition, Sabby Capital LLC raised its holdings by 0.22 million to 0.22 million shares.

With over 1.88 million Predictive Oncology Inc. (POAI) shares trading Tuesday and a closing price of $0.93 on the day, the dollar volume was approximately $1.75 million. The shares have shown a negative weekly performance of -21.36% and its price on 09/01/20 lost nearly -14.07%. Currently, there are 15.21M common shares owned by the public and among those 13.40M shares have been available to trade.

Insiders at the company have transacted a total of 13 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 13 of these insider trades were purchases, accounting for 1,624,939 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in Predictive Oncology Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and USAA Extended Market Index Fund. Vanguard Extended Market Index Fu owns 34404.0 shares of the company’s stock, all valued at over $55734.0. USAA Extended Market Index Fund bought 824.0 shares to bring its total holdings to over 1450.0 shares at a value of $2349.0. USAA Extended Market Index Fund now owns shares totaling to 0.01% of the shares outstanding.

Shares of Predictive Oncology Inc. (NASDAQ: POAI) opened at $1.07, down -$0.01 from a prior closing price of $1.08. However, the script later closed the day at $0.93, down -14.07%. The company’s stock has a 5-day price change of -21.36% and -45.41% over the past three months. POAI shares are trading -64.44% year to date (YTD), with the 12-month market performance down to -80.26% lower. It has a 12-month low price of $1.05 and touched a high of $6.25 over the same period. Currently, 1.88 million shares have been traded, compared to an average intraday trading volume of 961.22K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.49%, -38.92%, and -53.95% respectively.

Institutional ownership of Predictive Oncology Inc. (NASDAQ: POAI) shares accounts for 7.20% of the company’s 15.21M shares outstanding. Mutual fund holders own 12.43%, while other institutional holders and individual stakeholders account for 7.07% and 0.28% respectively.

It has a market capitalization of $14.37M and a beta (3y monthly) value of 1.61. The earnings-per-share (ttm) stands at -$6.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.55% over the week and 8.05% over the month.

Analysts forecast that Predictive Oncology Inc. (POAI) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for Next Year. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.